The importance of stereochemistry on the actions of vitamin D

Current Topics in Medicinal Chemistry

Volumn 11, Issue 7, 2011, Pages 840-859

  Chiellini, G ^a   DeLuca, H F ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

1, 25 dihydroxyvitamin D analog; Calcium homeostasis; Functions of vitamin D; Stereochemistry; Structure activity relationship; Tissue selective activity; Vitamin D metabolism

Indexed keywords

CALCITRIOL; VITAMIN D; VITAMIN D RECEPTOR;

CALCIUM HOMEOSTASIS; CHEMICAL MODIFICATION; DRUG INDICATION; DRUG POTENCY; DRUG SELECTIVITY; HYPERCALCEMIA; PSORIASIS; RENAL OSTEODYSTROPHY; REVIEW; RICKETS; SECONDARY HYPERPARATHYROIDISM; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; VITAMIN D METABOLISM;

ANIMALS; CALCIUM; DRUG DESIGN; HUMANS; HYDROCARBONS, ALICYCLIC; HYPERCALCEMIA; HYPERPARATHYROIDISM, SECONDARY; LIGANDS; MICE; ORGAN SPECIFICITY; OSTEOPOROSIS; PSORIASIS; RATS; RECEPTORS, CALCITRIOL; RENAL OSTEODYSTROPHY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; VITAMIN D;

EID: 79953662701     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/156802611795165016     Document Type: Review

References (171)

1. DeLuca, H. F. Vitamin D: the vitamin and the hormone. Fed. Proc, 1974, 33, 2211-2219.
2. Jones, G.; Strugnell, S. A.; DeLuca, H. F. Current understanding of the molecular actions of vitamin D. Physiol. Rev., 1998, 78, 1193-1231.
3. Giovannucci, E.; Liu, Y.; Hollis, B. W.; Rimm, E.B. 25-Hydroxyvitamin D and risk of myocardial infarction in men. Arch. Intern. Med., 2008, 168, 1174-1180.
4. Giovannucci, E. The epidemiology of vitamin D and cancer incidence and mortality: A review (United States). Cancer Causes Control, 2005, 16, 83-95.
5. Agranoff, B. W.; Goldberg, D. Diet and the geographical distribution of multiple sclerosis. Lancet, 1974, 2, 1061-1066.
6. Cantorna, M. T.; Zhu, Y.; Froicu, M.; Wittke, A. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am. J. Clin. Nutr., 2004, 80(Suppl), 1717S-1720S.
7. Haussler, M. R.; McCain, T. A. Vitamin D metabolism and action (First and Second of Two Parts). N Eng. J. Med., 1977, 297, 974-983 and 1041-1050.
8. Plum, L. A.; DeLuca, H. F. The functional metabolism and molecular biology of vitamin D action. Clin. Rev. Bone Miner. Metab., 2010, 7(1), 20-41.
9. Webb, A. R.; Kline, L.; Holick, M. F. Influence o season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J. Clin. Endocrinol. Metab., 1988, 67, 373-378.
10. Armas, L. A. G.; Dowell, S.; Akhter, M.; Duthuluru, S.; Huerter, C; Hollis, B. W.; Lund, R. L.; Heaney, R. P. Ultraviolet-B radiation increases serum 25 (OH) D levels: the effects of UVB dose and skin color. J. Am. Acad. Dermatol, 2007, 57, 588-593.
11. Velluz, L.; Amiard, G. Chimie organique-nourveau précurseur de la vitamin D3. Compt. Rend., 1949, 228, 1037-1038.
12. Madhok, T. C; DeLuca, H. F. Characteristics of the rat liver microsomal enzyme system converting cholecalciferol into 25-hydroxycholecalciferol. Eidence for the participation of cytochrome p-450. Biochem. J., 1979, 184, 491-499.
13. Cheng, J. B.; Motola, D. L.; Mangelsdorf, D. J.; Russell, D. W. De-orphanization of cytochrome P450 2R1: a microsomal vitamin D 25-hydroxylase. J. Biol. Chem., 2003, 278, 38084-38093.
14. Looker, A.C.; Pfeiffer, CM.; Lacher, D.A.; Schleicher, R.L.; Pic-ciano, M.F.; Yetley, E.A. Serum 25-hydroxyvitamin D status of the US population: 1988-1994 compared with 2000-2004. Am. J. Clin. Nutr., 2008, 88(6), 1519-1527.
15. Kim, C. J.; Kaplan, L. E.; Perwad, F.; Huang, N.; Sharma, A.; Choi, Y.; Miller, W. L.; Portale, A. A. Vitamin D 1 a-hydroxylase gene mutations in patients with 1 a-hydroxylase deficiency. J. Clin. Endocrinol. Metab., 2007, 92, 3177-3182.
16. Wang, J. T.; Lin, C-J.; Burridge, S. M.; Fu, G. K.; Labuda, M.; Portale, A. A.; Miller, W. L. Genetics of vitamin D 1 a-hydroxylase deficiency in 17 families. Am. J. Hum. Genet., 1998, 63, 1694-1702.
17. Dardenne, O.; Prud'Homme, J.; Arabian, A. Targeted inactivation of the 25-hydroxyvitamin D3-1 a-hydroxylase gene (CYP27B1) creates an animal model of pseudovitamin D-deficiency rickets. Endocrinology, 2001, 142, 3135-3141.
18. Yoshida, T.; Monkawa, T.; Tenenhouse, H. S.; Goodyer, P.; Shinki, T.; Suda, T.; Wakino, S.; Hayashi, M.; Saruta, T. Two novel 1 a-hydroxylase mutations in French-Canadians with vitamin D dependency rickets type I. Kidney Int., 1998, 54, 1437-1443.
19. Vanhooke, J. L.; Prahl, J. M.; Kimmel-Jehan, C; Mendelsohn, M.; Danielson, E. W.; Healy, K. D.; DeLuca, H.F. CYP27B1 null mice with LacZ reporter gene display no 25-hydroxyvitamin D3-1α-hydroxylase promoter activity in the skin. Proc. Natl. Acad. Sci. USA, 2006, 103, 75-80.
20. Akiyoshi-Shibata, M.; Sakaki, T.; Ohyama, Y. Further oxidation of hydroxycalcidiol by calcidiol 24-hydroxylase. Eur. J. Biochem., 1994, 224, 335-343.
21. Beckman, M. J.; Tadikonda, P.; Werner, E.; Prahl, J.; Yamada, S.; DeLuca, H.F. VanHuman 25-hydroxyvitamin D3-24-hydroxylase, a multicatalytic enzyme. Biochemistry, 1996, 35, 8465-8472.
22. Esvelt, R. P.; Schnoes, H. K.; DeLuca, H. F. Vitamin D3 from rat skins irradiated in vitro with ultraviolet light. Arch. Biochem. Bio-phys., 1978, 188, 282-286.
23. Omdahl, J. L.; Morris, H. A.; May, B. K. Hydroxylase enzymes of the vitamin D pathway: expression, function and regulation. Ann. Rev. Nutr., 2002, 22, 139-166.
24. DeLuca, H. F. In: The Transformation of a Vitamin into a Hormone: The Vitamin D Story. The Harvey Lectures, Series 75; Academic Press: New York 1981, pp. 333-379.
25. +2-sensing receptor from bovine parathyroid. Nature, 1993, 366, 575-580.
26. Baxter, L. A.; DeLuca, H. F. Stimulation of 25-hydroxyvitamin D3-1-hydroxylase by phosphate depletion. J. Biol. Chem., 1965, 251, 3158-3161.
27. Walling, M. W. Effects of 1,25-dihydroxyvitamin D3 on active intestinal inorganic phosphate absorption. In Vitamin D: Biochemical, chemical and clinical aspects related to calcium metabolism; Norman, A. W., Schaefer, K.; Coburn, J. W., Eds.; Walter de Gruyter: Berlin, 1977, pp. 321-330.
28. Liu, S.; Zhou, J.; Tang, W. Pathogenic role of Fgf23 in Hyp mice. Am. J. Physiol. Endocrinol. Metab., 2006, 291, E38-E49.
29. Berndt, T.; Kumar, R. Phosphatonins and the regulation of phosphate homeostasis. Annu. Rev. Physiol., 2007, 9, 4.1-4.19.
30. Shimada, T.; Kakitani, M.; Yamazaki Y.; Hasegawa, H.; Takeuchi, Y.; Fujita, T.; Fukumoto, S.; Tomizuka, K.; Yamashita, T. Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J. Clin. Invest., 2004, 113, 562-658.
31. Brumbaugh, P. F.; Haussler, M. R. Nuclear and cytoplasmic binding components for vitamin D metabolites. Life Sci., 1975, 16, 353-362.
32. Kream, B. E.; Reynolds, R. D.; Knutson, J. C; Eisman, J. A.; DeLuca, H. F. Intestinal cytosol binders of 1,25-dihydroxyvitamin D and 25-hydroxyvitamin D. Arch. Biochem. Biophys., 1976, 176, 779-787.
33. McCain, T. A.; Haussler, M. R.; Okrent, D.; Hughes, M. R. Partial purification of the chick intestinal receptor for 1,25-dihydroxyvitamin D by ion exchange and blue dextran-sepharose chromatography. FEBS Lett., 1978, 86, 65-70.
34. Simpson, RU; Hamstra, A.; Kendrick, N. C; DeLuca H. F. Purification of the receptor for 1α,25-dihydroxyvitamin D3 from chicken intestine. Biochemistry, 1983, 22, 2586-2594.
35. Baker, A. R.; McDonnell, D. P.; Hughes, M. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc. Natl. Acad. Sci USA, 1988, 85, 3294-3298.
36. Burmester, J. K.; Wiese, R. J.; Maeda, N.; DeLuca, H. F. Structure and regulation of the rat 1,25-dihydroxyvitamin D3 receptor. Proc. Natl. Acad. Sci. USA, 1988, 85, 9499-9502.
37. nd ed.; Feldman, D.; Pike, J. W.; Glorieux, F. H. Eds; Elsevier Academic Press, San Diego 2005, pp. 167-191.
38. McDonnell, D. P.; Scott, R. A.; Kerner, S. A.; O'Malley B. W.; Pike, J. W. Functional domains of the human vitamin D3 receptor regulate osteocalcin gene expression. Mol. Endocrinol., 1989, 3, 635-644.
39. Pike, J. W.; Meyer, M. B. The vitamin D receptor: New paradigms for the regulation of gene expression by 1,25-dihydroxyvitamin D3. Endocrinol. Metab. Clin. N. Am., 2010, 39, 255-269.
40. Takeda, E.; Yamamoto, H.; Taketani, Y.; Miyamoto, K. Vitamin D-dependent rickets type I and type II. Acta Paediatr. Jpn., 1997, 39, 508-513.
41. Bell, N. H.; Hamstra, A. J.; DeLuca, H. F. Vitamin D-dependent rickets type II: resistance of target organs to 1,25-dihydroxyvitamin D. N. Engl. J. Med., 1978, 298, 996-999.
42. Lieberman, U. A.; Eil, C; Marx, S. J. Clinical features of hereditary resistance to 1,25-dihydroxyvitamin D (hereditary hypocalcemic vitamin D resistant rickets type II). Adv. Exp. Med. Biol. 1986, 196, 391-406.
43. Balsan, S.; Garabedian, M.; Liberman, U. A.; Eil, C; Bourdeau, A.; Guillozo, H.; Grimberg R.; Le Deunff, M. J.; Lieberherr, M.; Guimbaud, P.; Broyer, M.; Marx, S. J. Rickets and alopecia with resistance to 1,25-dihydroxyvitamin D: Two different clinical courses with two different cellular defects. J. Clin. Endocrinol. Metab., 1983, 57, 803-811.
44. Yoshizawa, T.; Handa, Y.; Uematsu, Y.; Takeda, S.; Sekine, K.; Yoshihara, Y.; Kawakami, T.; Arioka, K.; Sato, H.; Uchiyama, Y.; Masushige, S.; Fukamizu, A.; Matsumoto, T.; Kato, S. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat. Genet., 1997, 16, 391-396.
45. nd ed.; Feldman, D.; Pike, J. W.; Glorieux, F. H. Eds.; Elsevier Academic Press, San Diego; 2005, 341-439.
46. Rochel, N.; Wurtz, J. M.; Mitschler, A.; Klaholz, B.; Moras, D. The crystal structure of the nuclear receptor for vitamin D bound to its natural ligand. Mol. Cell, 2000, 5, 173-179.
47. Vanhooke, J. L.; Benning, M. M.; Bauer, C. B.; Pike, J.W.; DeLuca, H.F. Molecular structure of the rat vitamin D receptor ligand binding domain complexed with 2-carbon-substituted vitamin D3 hormone analogues and a LXXLL-containing coactivator peptide. Biochemistry, 2004, 43, 4101-4110.
48. Umesono, K.; Murakami, K. K.; Thompson, C. C. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors. Cell, 1991, 65, 1255-1266.
49. Kim, S.; Yamazaki, M.; Zella, L. A. Activation of receptor activator of NF-kappaB ligand gene expression by 1,25-dihydroxyvtiamin D3 is mediated through multiple long-range enhancers. Mol. Cell. Biol, 2006, 26, 6469-6486.
50. Yu, V. C; Delsert, C; Andersen, B.; Holloway, J. M.; Devary, O. V.; Naar, A. M.; Kim, S. Y.; Boutin, J. M.; Glass, C. K.; Rosenfeld, M. G. RXRP: A coregulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements. Cell, 1991, 67, 1251-1266.
51. Carlberg, C; Seuter, S. The vitamin D receptor. Dermatol. Clin. 2007, 25, 515-523.
52. Rachez, C; Lemon, B.D.; Suldan, Z.; Bromleigh, V.; Gamble, M.; Näär, A.M.; Erdjument-Bromage, H.; Tempst, P.; Freedman, L.P. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature, 1999, 398, 824-828
53. O'Malley, B. W.; Kumar, R. Nuclear receptor coregulators in cancer biology. Cancer Res., 2009, 69, 8217-8222.
54. Underwood, J. L.; DeLuca, H. F. Vitamin D is not directly necessary for bone growth and mineralization. Am. J. Physiol, 1983, 246, E493-498.
55. Garabedian, M.; Tanaka, Y.; Holick, M. F.; DeLuca, H.F. Response of intestinal calcium transport and bone calcium mobilization to 1,25-dihydroxyvitamin D3 in thyroparathyroidectomized rats. Endocrinology, 1974, 94, 1022-1027.
56. Yamamoto, M.; Kawanobe, Y.; Takahashi, H.; Shimazawa, E.; Kimura, S.; Ogata, E. Vitamin D deficiency and renal calcium transport in the rat. J. Clin. Invest., 1984, 74, 507-513.
57. Silver, J.; Naveh-Many, T.; Mayer, H.; Schmeizer, H. J.; Popvtzer, M. M. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J. Clin. Invest., 1986, 78, 1296-1301.
58. Brown, A. J.; Slatopolsky, E. Drug insight: vitamin D analogs in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. Nat. Clin. Pract. Endocrinol. Metab., 2007, 3, 134-144.
59. Reichrath, J.; Muller, S. M.; Kerber, A.; Baum, H. P.; Bahmer, F. A. Biologic effects of topical calcipotriol (M903) treatment in psoriatic skin. J. Am. Acad. Dermatol, 1997, 36, 19-28.
60. Krämer, C; Seltmann, H.; Seifert, M.; Tilgen, W.; Zouboulis, C. C; Reichrath, J. Characterization of the vitamin D endocrine system in human sebocytes in vitro. J. Steroid Biochem. Mol. Biol, 2009, 113, 9-16.
61. Veldman, C. M.; Cantorna, M. T.; DeLuca, H. F. Expression of 1,25-dihydroxyvitamin D3 receptor in the immune system. Arch. Biochem. Biophys., 2000, 374, 334-338.
62. Bhalla, A. K.; Amento, E. P.; Clemens, T. L.; Holick, M. F.; Krane, S. M. Specific high-affinity receptors for 1,25-dihydroxyvitamin D3 in human peripheral blood mononuclear cells: presence in monocytes and induction in T lymphocytes following activation. J. Clin. Endocrinol. Metab., 1983, 57, 1308-1310.
63. Liu, P.T.; Stenger, S.; Li, H.; Wenzel, L.; Tan, B.H.; Krutzik, S.R.; Ochoa, M.T.; Schauber, J.; Wu, K.; Meinken, C; Kamen, D.L.; Wagner, M.; Bals, R.; Steinmeyer, A.; Zügel, U.; Gallo, R.L.; Eis-enberg, D.; Hewison, M.; Hollis, B.W.; Adams, J.S.; Bloom, B.R.; Modlin, R.L. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science, 2006, 311(5768), 1770-1773.
64. Provvedini, D. M.; Tsoukas, C. D.; Deftos, L. J.; Manolagas, S.D. 1,25-Dihydroxyvitamin D3 receptors in human leukocytes. Science, 1983, 221, 1181-1183.
65. Yang, S.; Smith, C; Prahl, J. M.; Luo, X.; DeLuca, H. F. Vitamin D deficiency suppresses cell-mediated immunity in vivo. Arch. Biochem. Biophys., 1993, 303, 98-106.
66. Yang, S.; Smith, C; Deluca, H.F. 1α,25-Dihydroxyvitamin D3 and 19-nor-1α,25-dihydroxyvitamin D2 suppress immunoglobulin production and thymic lymphocyte proliferation in vivo. Biochim. Biophys. Acta, 1993, 1158, 279-286.
67. Bertone-Johnson, E. R. Vitamin D and breast cancer. Ann. Epidemiol, 2009, 19, 461-466.
68. Garland, C. F.; Garland, F. C; Gorham, E. D.; Lipkin, M.; New-mark, H.; Mohr, S. B.; Holick, M. F. The role of vitamin D in cancer prevention. Am. J. Public Health, 2006, 96, 252-261.
69. Masuda, S.; Jones, G. Promise of vitamin D analogues in the treatment of hyperproliferative conditions. Mol. Cancer Ther., 2006, 5, 797-808.
70. Wang, Y.; Becklund, B. R.; DeLuca, H. F. Identification of a highly specific and versatile vitamin D receptor antibody. Arch. Biochem. Biophys., 2010, 494, 166-177.
71. Schubert, L.; DeLuca, H. F. Hypophosphatemia is responsible for skeletal muscle weakness of vitamin D deficiency. Arch. Biochem. Biophys., 2010, 500(2), 157-161
72. Penckofer, S.; Kouba, J.; Byrn, M.; Estwing Ferrans, C. Vitamin D and depression: Where is all the sunshine? Issues Mental Health, 2010, 31, 385-393.
73. Buell, J. S.; Dawson-Hughes, B.; Scott, T. M.; Weiner, D. E.; Dal-lal, G. E.; Qui, W. Q.; Bergethon, P.; Rosenberg, I. H.; Folstein, M. F.; Patz, S.; Bhadelia, R. A.; Tucker, K.L. 25-Hydroxyvitamin D, dementia, and cerebrovascular pathology in elders receiving home services. Neurology, 2010, 74, 18-26.
74. Wang, T. T.; Nestel, F. P.; Bourdeau, V.; Nagal, Y.; Wang, Q.; Liao, J.; Tavera-Mendoza, L.; Lin, R.; Hanrahan, J. W.; Mader, S.; White, J. H. Cutting edge: 1,25-dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J. Immunol, 2004, 173, 2909-2912.
75. Giovannucci, E.; Liu, Y.; Willett, W.E. Cancer incidence and mortality and vitamin D in Black and White male health professionals. Cancer Epidemiol. Biomarkers Prev., 2006, 15, 2467-2472.
76. Chesney, R. W. Vitamin D and the magic mountain: The anti-infectious role of the vitamin. J. Ped., 2010, 156, 698-703.
77. Kong, J.; Qiao, G.; Zhang, Z.; Liu S. Q.; Li, Y. C. Targeted vitamin D receptor expression in juxtaglomerular cells suppresses renin expression independent of parathyroid hormone and calcium. Kidney Int., 2008, 74, 1577-1581.
78. Zhou, C; Lu, F.; Cao, K.; Xu, D.; Goltzman, D.; Miao, D. Calcium-independent and 1,25(OH)2D3-dependent regulation of the renin-angiotensin system in 1 a-hydroxylase knockout mice. Kidney Int., 2008, 74, 170-179.
79. nd ed, Feldman, D.; Pike, J. W.; Glorieux, F. H., Eds.; Elsevier: San Diego, CA 2005, pp. 381-411.
80. DeLuca, H. F.; Burmester, J.; Darwish, H.; Krisinger, J. Molecular Mechanism of the Action of 1,25-Dihydroxyvitamin D3. In: Comprehensive Medicinal Chemistry; Hansch, C, Sammes, P. G.,Taylor, J. B., Eds.; Pergamon Press: Oxford, 1991; Vol. 3, pp. 1129-1143.
81. Norman, A. W.; Bouillon, R.; Thomasset, M. Eds., Vitamin D, A Pluripotent Steroid Hormone: Structural Studies, Molecular Endocrinology and Clinical Applications; Walter de Gruyter: Berlin, 1994.
82. Chawla, A.; Repa, J. J.; Evans, R. M.; Mangelsdorf, D. J. Nuclear receptors and lipid physiology: opening the X-files. Science, 2001, 294, 1866-1870.
83. Malloy, P. J.; Pike, J. W.; Feldman, D. The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocr. Rev., 1999, 20, 156-188.
84. Evans, R. M. The steroid and thyroid hormone receptor superfa-mily. Science, 1988, 240, 889-895.
85. Feldman, D.; Glorieux, F. H.; Pike, J. W. Vitamin D; Academic Press: New York, 1997.
86. DeLuca, H. F.; Paaren, H. E.; Schnoes, H. K. Vitamin D and calcium metabolism. Top. Curr. Chem., 1979, 83, 1-65.
87. Bouillon, R.; Okamura, W. H.; Norman, A. W. Structure-function relationship in the vitamin D endocrine system. Endocr. Rev., 1995, 16, 200-257.
88. Okamura, W. H.; Norman, A. W.; Wing, R. M. Vitamin D concerning the relationship between molecular topology and biological function. Proc. Natl. Acad. Sci. USA, 1974, 71, 4194-4197.
89. Sicinski, R. R.; Glebocka, A.; Plum, L. A.; DeLuca, H. F. Design, synthesis, and biological evaluation of a 1,25-dihydroxy-19-norvitamin D3 analogue with a frozen A-ring conformation. J. Med. Chem., 2007, 50, 6154-6164.
90. Ishida, H.; Shimizu, M.; Yamamoto, K.; Iwasaki, Y.; Yamaguchi, K. Synthesis of 1-alkyl-1,25-dihydroxyvitamin D3. J. Org. Chem., 1995, 60, 1828-1833.
91. Fujishima, T.; Harada, Y.; Katsuhiro, K.; Nakagawa, K.; Tanaka, M.; Okano, T.; Takayama, H. Efficient Synthesis and Biological Evaluation of 1-Methyl-1,25-Dihydroxyvitamin D3. In: Vitamin D endocrine system: structural, biological, genetic and clinical aspects; Norman, A. W.; Bouillon, R.; Thomasset, M., Eds.; Riverside: Univ California-Riverside Printing and Reprographics, 2000; pp. 93-96
92. Shimizu, M.; Iwasaki, Y.; Yamada, S. 4,4-Difluoro-1α,25-dihydroxyvitamin D3: Analog to probe A-ring conformation in vitamin D-receptor complex. Tetrahedron Lett., 1999, 40, 1697-1700.
93. Yamada, S.; Shimizu, M.; Yamamoto, K. Structure-function relationships of vitamin D including ligand recognition by vitamin D receptor. Med. Res. Rev., 2003, 23, 89-115.
94. Konno, K.; Maki, S.; Fujiishima, T.; Liu, Z.; Miura, D.; Chokki, M.; Takayama, H. A novel and practical route to A-ring enyne syn-thon for 1α,25-dihydroxyvitamin D3 analogs: Synthesis of A-ring diastereomers of 1α,25-dihydroxyvitamin D3 and 2-methyl-1,25-dihydroxyvitamin D3. Bioorg. Med. Chem. Lett, 1998, 8, 151-156.
95. Konno, K.; Fujiishima, T.; Maki, S.; Liu, Z.; Miura, D.; Chokki, M.; Ishizuka, S.; Yamaguchi, K.; Kan, Y.; Kurikara, M.; Miyata, N.; Smith, C; DeLuca, H.F.; Takayama, H. Synthesis, biological evaluation, and conformational analysis of A-ring diastereomers of 2-methyl-1,25-dihydroxyvitamin D3 and their 20-epimers: Unique activity profiles depending on the stereochemistry of the A-ring and at C-20. J. Med. Chem., 2000, 43, 4247-4265.
96. Fujiishima, T.; Liu, Z.; Konno, K.; Nakagawa, K.; Okano, T.; Yamaguchi, K.; Takayama, H. Highly potent cell differentiation-inducing analogues of 1α,25-dihydroxyvitamin D3: Synthesis and biological activity of 2-methyl-1,25-dihydroxyvitamin D3 with side-chain modifications. Bioorg. Med. Chem., 2001, 9, 525-535.
97. Suhara Y.; Nihei, K.; Tanigawa, H.; Fujishima, T.; Konno, K.; Nakagawa, K.; Okano, T.; Takayama, H. Synthesis and biological evaluation of novel 2a -substituted 1α,25-dihydroxyvitamin D3 analogues. Bioorg. Med. Chem. Lett., 2000, 10, 1129-1132.
98. Nishii, Y.; Sato, K.; Kobayashi, T. The development of vitamin D analogues for the treatment of osteoporosis. Osteoporosis Int. 1, Suppl, 1993, S190-S193.
99. Kittaka, A.; Suhara, Y.; Takayanagi, H.; Fujishima, T.; Kurihara, H.; Takayama, H. A concise and efficient route to 2a -(co-hydroxyalkoxy)-1α,25-dihydroxyvitamin D3: Remarkably high affinity to vitamin D receptor. Org. Lett., 2000, 10, 1129-1132.
100. Matsumoto, T.; Miki, T.; Hagino, H.; Sugimoto, T.; Okamoto, S.; Hirota, T.; Tanigawara, Y.; Hayashi, Y.; Fukunaga, M.; Shiraki, M.; Nakamura, T. A New Active Vitamin D, ED-71, Increases Bone mass in osteoporotic patients under vitamin d supplementation: a randomized, double-blind, placebo-controlled clinical trial. J. Clin. Endocrinol. Metab., 2005, 90, 5031-5036.
101. Perlman, K. L.; Sicinski, R. R.; Schnoes, H. K.; DeLuca, H. F. 1α,25-dihydroxy-19-norvitamin D3, a novel vitamin d-related compound with potential therapeutic activity. Tetrahedron Lett., 1990, 31, 1823-1824.
102. Perlman, K. L.; Swenson, R. E.; Paaren, H. E.; Schnoes, H. K.; DeLuca, H. F. Novel synthesis of 19-norvitamin d compounds. Tetrahedron Lett., 1991, 32, 7663-7666.
103. Bouillon, R.; Sarandeses, L. A.; Allewaert, K.; Zhao, J.; Mascare-nas, J. L.; Mourino, A.; Vrielynck, S.; DeClercq, P.; Vandewalle, M. Biological activity of dihydroxylated 19-nor-(pre)vitamin D3. J. Bone Miner. Res., 1993, 8, 1009-1015.
104. Slatopolsky, E.; Finch, J.; Ritter, C; Denda, M.; Morrissey, J.; Brown, A.; DeLuca, H. A new analog of calcitriol, 19-Nor 19-nor-1,25-(OH)2D2, suppresses parathyroid hormone secretion in uremic rats in the absence of hypercalcemia. Am. J. Kidney Dis., 1995, 26, 852-860.
105. Llack, F.; Yudd, M. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism. Am. J. Kidney Dis., 2001, 38, S45-50.
106. Thadhani, R.; Wolf M. Vitamin D in patients with kidney disease: cautiously optimistic. Adv. Chronic Kidney Dis., 2007, 14, 22-26.
107. Mikami, K.; Osawa, A.; Isaka, A.; Sawa, E.; Shimizu, M.; Terada, M.; Kubodera, N.; Nakagawa, K.; Tsugawa, N.; Okano, T. "Symmetry" in the synthesis of the a-ring of a vitamin d hybrid analogue with significant transactivation activity: a combinatorial sequence of regioselective propiolate-ene, catalytic enantioselective epoxida-tion and carbonyl-ene cyclization reactions. Tetrahedron Lett., 1998, 39, 3359-3362.
108. Okano, T.; Nakagawa, K.; Kubodera, N.; Ozono, K.; Isaka, A.; Osawa, A.; Terada, M.; Mikami, K. Catalytic asymmetric synthesis and biological activities of singly dehydroxylated 19-nor-1α,25-dihydroxyvitamin d3 a-ring analogs in cancer cell differentiation and apoptosis. Chem. Biol, 2000, 7, 173-184.
109. Sicinski, R. R.; Perlman, K. L.; DeLuca, H. F. Synthesis and biological activity of 2-hydroxy and 2-alkoxy analogs of 1α,25-dihydroxy-19-norvitamin D3. J. Med. Chem., 1994, 37, 3730-3738.
110. Sicinski, R. R.; Prahl, J. M.; Smith, C. M.; DeLuca, H. F. New 1α,25-dihydroxy-19-norvitamin d3 compounds of high biological activity: synthesis and biological evaluation of 2-hydroxymethyl, 2-methyl and 2-methylene analogues. J. Med.Chem. 1998, 41, 4662-4674.
111. DeLuca, H. F.; Plum, L. A.; Clagett-Dame, M.; Shevde, N.K.; Pike, J. W.; Sicinski, R. R. 2- In: Carbon-Modified Analogs of 19-Nor-1 a,25-Dihydroxyvitamin D3. Vitamin D; Feldman, D.; Pike, J.W.; Glorieux, F. H.; Eds.; Elsevier Academic Press: New York, 2005, Chapter 87, pp. 1543-1555.
112. Shevde, N. K.; Plum, L. A.; Clagett-Dame, M.; Yamamoto, H.; Pike, J. W.; DeLuca, H. F. A Potent analog of 1α,25-dihydroxyvitamin d3 selectively induces bone formation. Proc. Natl. Acad. Sci. USA, 2002, 99, 13487-13491.
113. Glebocka, A.; Sicinski, R. R.; DeLuca, H. F. New derivative of 1α, 25-dihydroxy-19-norvitamin d3 with 3'-alkoxypropylidene moiety at c-2: synthesis, biological activity and conformational analysis. J. Steroid Biochem. Mol. Biol. 2004, 89(90), 25-30.
114. Plum, L. A.; Prahl, J. M.; Ma, X.; Sicinski, R. R.; Gowlugari, S.; Clagett-Dame, M.; DeLuca, H. F. Biologically active noncalcemic analogs of 1α,25-dihydroxyvitamin d with an abbreviated side chain containing no hydroxyl. Proc. Natl. Acad. Sci. USA, 2004, 101, 6900-6904.
115. Grzywacz, P.; Plum, L. A.; Sicinska, W.; Sicinski, R. R.; Prahl, J. M.; DeLuca, H. F. 2-Methylene analogs of 1α-hydroxy-19-norvitamin d3: synthesis, biological activities and docking to the ligand binding domain of the rat vitamin D receptor. J. Steroid Biochem. Mol. Biol, 2004, 89(90), 13-17.
116. Yoshida, A.; Ono, K.; Suhara, Y.; Saito, N.; Takayama, H.; Kit-taka, A. Efficient and convergent coupling route for the shortstep synthesis of enantiopure 2a- and 2P-alkylated 1α,25-dihydroxy-19-norvitamin D3 analogues. Synlett, 2003, 1175-1179.
117. Ono, K.; Yoshida, A.; Saito, N.; Fujishima, T.; Honzawa, S.; Suhara, Y.; Kishimoto, S.; Sugiura, T.; Waku, K.; Takayama, H.; Kit-taka, A. Efficient synthesis of 2-modified 1α,25-dihydroxy-19-norvitamin d3 with julia olefination: high potency in induction of differentiation on HL-60 Cells. J. Org. Chem., 2003, 68, 7407-7415.
118. Mikami, K.; Koizumi Y.; Osawa, A.; Terada, M.; Takayama, H.; Nakagawa, K.; Okano, T. BINOL-Ti-catalized carbonyl-ene cyclization by tuning the 6-Br-ligand for the synthesis of 2-methyl-19-nor-22-oxa vitamin d analogue with significant differentiation activity. Synlett, 1999, 1899-1902.
119. Shimizu, M.; Iwasaki, Y.; Shibamoto, Y.; Sato, M.; DeLuca, H. F.; Yamada, S. Novel synthesis of 2-substituted 19-norvitamin D A-ring phosphine oxide from d-glucose as a building Block. Bioorg. Med. Chem. Lett. 2003, 13, 809-812.
120. Sanchez-Abella, L.; Fernandez, S.; Verstuyf, A.; Verlindem, L.; Gotor, V.; Ferrero, M. Sinthesis, conformational analysis, and biological evaluation of 19-nor-vitamin d3 analogues with a-ring modifications. J. Med. Chem. 2009, 52, 6158-6162.
121. Sicinski, R. R.; Rotkiewicz, P.; Kolinski, A.; Sicinska, W.; Prahl, J. M.; Smith, C. M.; DeLuca, H. F. 2-Ethyl and 2-ethylidene analogues of 1α,25-dihydroxy-19-norvitamin D3: synthesis, conformational analysis, biological activities, and docking to the modeled rVDR ligand binding domain. J. Med. Chem. 2002, 45, 3366-3380.
122. Glebocka, A.; Sicinski, R. R.; Plum, L. A.; Clagett-Dame, M.; DeLuca, H. F. New 2-alkylidene 1α,25-dihydroxy-19-norvitamin D3 analogues of high intestinal activity: synthesis and biological evaluation of 2-(3'-alkoxypropylidene) and 2-(3'-hydroxy-propylidene) derivatives. J. Med. Chem., 2006, 49, 2909-2920.
123. DeLuca, H. F.; Plum, L. A.; Clagett-Dame, M. Selective analogs of 1α,25-Dihydroxyvitamin D3 for the study of specific functions of Vitamin D. J. Steroid Biochem. Mol. Biol, 2007, 103, 263-268.
124. Binderup, L.; Latini, S.; Binderup, E.; Bretting, C; Calverley, M.; Hansen, K. 20-Epi-vitamin D3 analogues: A novel class of potent regulators ofcell growth and immune responses. Biochem. Pharmacol, 1991,42,1569-1575.
125. Abe, J.; Takita, Y.; Nakano, T.; Miyaura, C; Suda, T.; Nishii, Y. A synthetic analogue of vitamin D3, 22-oxa-1α,25-dihydroxyvitamin D3, is a potent modulator of in vivo immunoregulating activity without inducing hypercalcemia in mice. Endocrinology, 1989, 124, 2645-2647
126. Kubodera, N.; Miyamoto, K.; Akiyama, M.; Matsumoto, M.; Mori, T. Synthetic studies of vitamin D analogues. Synthesis and differentiation-inducing activity of 1α,25-dihydroxy-23-oxa, thia-, and azavitamin D3. Chem. Pharm. Bull, 1991, 39, 3221-3224.
127. Chen, T.C.; Persons, K.; Uskokovic, M. R.; Horst, R. L.; Holick, M. F. An evaluation of 1,25-dihydroxyvitamin D3 analogues on the proliferation and differentiation of cultured human keratinocytes, calcium metabolism and the differentiation of human HL-60 cells. J. Nutr. Biochem., 1993, 4, 49-57.
128. Zhou, J. Y., Norman, A. W.; Akashi, M.; Chen, D. L.; Uskokovic, M. R.; Aurrecoechea, J. M.; Dauben, W. G.; Okamura, W. H.; Koeffler, H. P. Development of a novel 1α,25(OH)2-vitamin D3 analog with potent ability to induce HL-60 cell differentiation without modulating calcium metabolism. Blood 1991, 78, 75-82.
129. Ostrem, V. K.; Tanaka, Y.; Prahl, J.; DeLuca, H. F.; Ikekawa, N. 24- and 26-homo-1α,25-dihydroxyvitamin D3: preferential activity in inducing differentiation of human leukemia cells HL-60 in vitro. Proc. Natl. Acad. Sci. USA, 1987, 84, 2610-2614.
130. Perlman, K.; Kutner, A.; Prahl, J.; Smith, C; Inaba, M.; Schnoes, H. K.; DeLuca, H.F. 24-Homologated 1α,25-dihydroxyvitamin D3 compounds:separation of calcium and cell differentiation activities. Biochemistry, 1990, 29, 190-196.
131. Eguchi, T.; Ikekawa, N.; Sumitani, K.; Kumegawa, M.; Higuchi, S.; Otomo, S. Effect on carbon lengthening at the side chain terminal of 1α,25-dihydroxyvitamin D3 for calcium regulating activity. Chem. Pharm. Bull, 1990, 38, 1246-1249.
132. Honda, A.; Mori, Y.; Otomo, S.; Ishizuka, S.; Ikekawa, N. Effects of novel 26,27-dialkyl analogs of 1α,25-dihydroxyvitamin D3 on differentiation-inducing activity of human promyelocytic leukemia (HL-60) cells in serum-supplemented or serum-free culture. Steroid, 1991, 56, 142-147.
133. Danielsson, C; Nayeri, S.; Wiesinger, H.; Thieroff-Ekerdt, R.; Carlberg, C. Potent gene regulatory and antiproliferative activities of 20-methyl analogues of 1α,25 dihydroxyvitamin D3. J. Cell. Biochem., 1996, 63, 199-206.
134. Shiina, Y.; Abe, E.; Miyaura, C; Tanaka, H.; Yamada, S.; Ohmori, M.; Nakayama, K.; Takayama, H.; Matsunaga, I.; Nishii, Y.; De-Luca, H. F.; Suda, T. Biological activity of 24,24-difluoro-1α,25-dihydroxyvitamin D3 and 1α,25-dihydroxyvitamin D3 26,23-lactone in inducing differentiation of human myeloid leukemia cells. Arch. Biochem. Biophys., 1983, 220, 90-94.
135. Inaba, M.; Okuno, S.; Nishizawa, Y.; Yukioka, K.; Otani, S.; Ma-tsui-Yuasa, I.; Morisawa, S.; DeLuca, H. F.; Morii, H. Biological activity of fluorinated vitamin D analogs at C-26 and C-27 on human promyelocytic leukemia cells, HL-60. Arch. Biochem. Biophys., 1987, 258, 421-425.
136. Sicinski, R. R.; Perlman, K. L.; Prahl, J.; Smith, C; DeLuca, H.F. Synthesis and biological activity of 1α,25-dihydroxy-18-norvitamin D3 and 1α,25-dihydroxy-18,19-dinorvitamin D3. J. Med. Chem., 1996, 39, 4497-4506.
137. Ostrem, V. K.; Lau, W. F.; Lee, S. H.; Perlman, K.; Prahl, J.; Schnoes, H. K.; DeLuca, H. F. Induction of monocytic differentiation of HL-60 cells by 1α,25-dihydroxyvitamin D analogs. J. Biol. Chem., 1987, 262, 14164-14171.
138. Calverley, M. J. Synthesis of MC-903, a biologically active vitamin D metabolite analog. Tetrahedron, 1987, 43, 4609-4619.
139. Murayama, E.; Miyamoto, K.; Kubudera, N.; Mori, T.; Matsunaga, I. Synthetic studies of vitamin D analogues. VIII. Synthesis of 22-oxavitamin D3 analogues. Chem. Pharm. Bull, 1986, 34, 4410-4413.
140. Baggiolini, E. G.; Partridge, J. J.; Shivey, S. J.; Truitt, G. A.; Vskokovic, M. R. Cholecalciferol 23-yne derivatives, their pharmaceutical compositions, their use in the treatment of calcium-related diseases, and their antitumor activity. US 4,804,502. Chem. Abstr., 1989, 111, 58160d.
141. Binderup, E.; Calverley, M. J.; Binderup, L. Synthesis and Biological Activity of 1-Hydroxylated Vitamin D Analogues With Polyunsaturated Side Chains. In: Vitamin D Gene Regulation, Structure-Function Analysis and Clinical Application. Norman, A. W.; Bouillon, R.; Thomasset, M. Eds. Berlin: de Gruyter, 1991, pp. 192-193.
142. Hansen, K.; Calverley, M.J.; Binderup, L. Synthesis and Biological Activity of 22-OXA Vitamin D Analogues. In: Vitamin D Gene Regulation, Structure-Function Analysis and Clinical Application. Norman, A. W.; Bouillon, R.; Thomasset, M. Eds. Berlin: de Gruyter, 1991, 161-162.
143. Yamamoto, K.; Sun, W.Y.; Ohta, M.; Hamada, K.; DeLuca, H.F.; Yamada, S. Conformationally restricted analogs of 1-alpha, 25-dihydroxyvitamin D3 and its 20-epimer: compounds for study of the three-dimensional structure of vitamin D responsible for binding to the receptor. J. Med. Chem., 1996, 39, 2727-2737.
144. Peleg, S.; Sastry, M.; Collins, E. D.; Bishop, J. E.; Norman, A. W. Distinct conformational changes induced by 20-epi analogues of 1αlpha,25-dihydroxyvitamin D3 are associated with enhancedacti-vation of the vitamin D receptor. J. Biol. Chem., 1995, 270, 10551-10558.
145. Yamamoto, H.; Shevde, N.K.; Warrier, A.; Plum, L.A.; DeLuca, H.F.; Pike, J.W. 2-Methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 potently stimulates gene-specific DNA binding of the vitamin D receptor in osteoblasts. J. Biol. Chem., 2003, 278, 31756-31765.
146. Plum, L.A.; Fitzpatrick, L.A.; Ma, X.; Binkley, N.C.; Zella, J.B.; Clagett-Dame, M.; DeLuca, H.F. 2MD, a new anabolic agent for osteoporotic treatment. Osteoporos. Int., 2006, 17, 704-715.
147. Ke, H.Z.; Qi, H.; Crawford, D.T.; Simmons, H.A.; Xu, G.; Li, M.; Plum, L.; Clagett-Dame, M.; DeLuca, H.F.; Thompson, D.D.; Brown, T.A. A new vitamin D analog, 2MD, restores trabecular and cortical bone mass and strength in ovariectomized rats with established osteopenia. J Bone Miner Res., 2005, 10, 742-755.
148. Xue, Y.; Karaplis, A.C.; Hendy, G.N.; Goltzman, D.; Miao, D. Exogenous 1,25-dihydroxyvitamin D3 exerts a skeletal anabolic effect and improves mineral ion homeostasis in mice that are homozygous for both the 1αlpha-hydroxylase and parathyroid hormone null alleles. Endocrinology, 2006, 47(10), 4801-4810.
149. Schwinn, M.K.; DeLuca, H.F. Differential recruitment of coactiva-tors to the vitamin D receptor transcriptional complex by 1α, 25-dihydroxyvitamin D3 analogs. Arch. Biochem. Bioph., 2007, 443-451.
150. Tocchini-Valentini, G.; Rochel, N.; Wurtz, J.M.; Mitschler, A.; Moras, D. Crystal structures of the vitamin D receptor complexed to superagonist 20-epi ligands. Proc. Natl. Acad. Sci. USA, 2001, 98, 5491-5496.
151. Vanhooke, J.L.; Tadi, B.P.; Benning, M.M.; Plum, L.A.; DeLuca, H.F. New analogs of 2-methylene-19-nor-(20S)-1,25-dihydroxyvitamin D3 with conformationally restricted side chains: Evaluation of biological activity and structural determination of VDR-bound conformations. Arch. Biochem. Biophys, 2007, 460, 161-165.
152. Rochel, N.; Hourai, S.; Perez-Garcia, X.; Rumbo, A.; Mourino, A.; Moras, D. Crystal structure of the vitamin D nuclear receptor ligand binding domain in complex with a locked side chain analog of calcitriol. Arch. Biochem. Biophys, 2007, 460, 172-176.
153. Eelen, G.; Verlinden, L.; Bouillon, R.; De Clercq, P.; Muñoz, A.; Verstuyf A. CD-ring modified vitamin D(3) analogs and their superagonistic action. J. Steroid Biochem. Mol. Biol, 2010, 121(1-2),417-419.
154. Verstuyf, A.; Verlinden, L.; Van Baelen, H.; Sabbe, K.; D'Hallewyn, C; De Clercq, P.; Vandewalle, P.; Bouillon, R. The biological activity of nonsteroidal vitamin D hormone analogs lacking both the C- and D-rings. J. Bone Miner. Res., 1998, 13, 549-558.
155. Verstuyf, A.; Verlinden, L.; van Etten, E.; Shi, L.; Wu, Y.; D'Halleweyn, C; Van Haver, D.; Zhu, G.D.; Chen, Y.J.; Zhou, X.; Haussler, M.R.; De Clercq, P.; Vandewalle, M.; Van Baelen, H.; Mathieu, C. Bouillon, R. Biological activity of CD-ring modified 1αlpha,25-dihydroxyvitamin D analogues: C-ring and five-membered D-ring analogues, J. Bone Miner. Res., 2000, 15, 237-252.
156. Plonska-Ocypa, K.; Sicinski, R.R.; Plum, L.A.; Grzywacz, P.; Frelek, J.; Clagett-Dame, M.; DeLuca, H.F. 13-Methyl-substituted des-C,D analogs of (20S)-1α,25-dihydroxy-2-methylene-19-norvitamin D3 (2MD): Synthesis and biological evaluation. Bioorg. Med. Chem., 2009, 17, 1747-1763.
157. Norman, A.W.; Okamura, W.H.; Farach-Carson, M.C.; Allewaert, K.; Branisteanu, D.; Nemere, I.; Muralidharan, K.R.; Bouillon, R. Structure-function studies of 1,25-dihydroxyvitamin D3 and the vitamin D endocrine system. 1,25-dihydroxy-pentadeuterio-previtamin D3 (as a 6-s-cis analog) stimulates nongenomic but not genomic biological responses. J. Biol. Chem., 1993, 268, 13811-13819.
158. Dauben, W.G.; Kohler, B.; Roesle, A. Synthesis of 6-fluorovitamin D3. J. Org. Chem., 1985, 50, 2007-2010.
159. Wilhelm, F.; Dauben, W.G.; Kohler, B.; Roesle, A.; Norman, A.W. 6-Fluorovitamin D3: a new antagonist of the biological actions of vitamin D3 and its metabolites which interacts with the intestinal receptor for 1α,25(OH)2-vitamin D3 Arch. Biochem. Biophys, 1984, 233, 127-132.
160. Sheves, M.; Mazur, Y. Equilibria in vitamin D3. Preparation and properties of 6-methylvitamin D3 and its isomers. J. Chem. Soc, Chem. Commun., 1977, 21-22.
161. Yamada, S.; Suzuki, T.; Takayama, H. Novel regioselective C-6 and C-19 alkylation of vitamin D3 via its sulfur-dioxide adducts. Tetrahedron Lett., 1981, 22, 3085-3088.
162. Sokolowska, K.; Mourino, A.; Sicinski, R.R.; Sigueiro, R.; Plum, L.A.; DeLuca, H.F. Synthesis and biological evaluation of 6-methyl analog of 1α,25-dihydroxyvitamin D3. J. Steroid Bioch. Mol. Biol, 2010, 121(1-2),29-33
163. Nguyen, T.M.; Adiceam, P.; Kottler, M.L.; Guillozo, H.; Rizk-Rabin, M.; Brouillard, F.; Lagier, P.; Palix, C; Garnier, J.M.; Ga-rabedian, M. Tryptophan missense mutation in the ligand-binding domain of the vitamin D receptor causes severe resistance to 1,25-dihydroxyvitamin D. J. Bone Miner. Res., 2002, 17, 1728-1737.
164. Choi, M.; Yamamoto, K.; Itoh, T.; Makishima, M.; Mangelsdorf, D.J.; Moras, D.; DeLuca, H.F.; Yamada, S. Interaction between vitamin D receptor and vitamin D ligands: two-dimensional alanine scanning mutational analysis. Chem. and Biol, 2003, 10, 261-270.
165. Strugnell, S.A.; DeLuca, H.F. The vitamin D receptor-structure and transcriptional activation. Proc. Soc. Exp. Biol. Med., 1997, 215, 223-228.
166. Solomon, C; Macoritto, M.; Gao, X.L.; White, J.H.; Kremer, R. The unique tryptophan residue of the vitamin D receptor is critical for ligand binding and transcriptional activation. J. Bone Miner. Res., 2001, 16, 39-45.
167. Sicinski, R.R.; DeLuca, H.F. Synthesis of 6,7-diaza-19-norvitamin D compounds. BioorgMed. Chem., 1995, 5, 899-904.
168. Kitaev, Y.P.; Nivorozhkin, L.E.; Plegontov, S.A., Raevski, O.A.; Titova, S.Z. Microwave spectra of diaza-compounds. Dokl. Akad. Nauk. SSSr Ser Khim., 1968, 440, 203-207.
169. Boehm, M.F.; Fitzgerald, P.; Zou, A.; Elgort, M. G.; Bischoff, E. D.; Mere, L.; Mais, D. W.; Bissonnette, R. P.; Heyman, R. A.; Na-dzan, A. M.; Reichman, M.; Allegretto, E. A. Novel nonsecosteroi-dal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3. Chem. Biol., 1999, 6, 265-275.
170. Kubodera, N.; Sato, K.; Nishii, Y. Characteristics of 22-oxacalcitriol (OCT) and 2beta-(3-hydroxypropoxy)-calcitriol (ED-71). In Vitamin D; Feldman, D; Glorieux, F.H.; Pike, J.W., Eds.; Academic Press, San Diego, CA. 1997, Chapter 63, pp. 1071-1105.
171. Kissmeyer, A.M.; Binderup, L. Calcipotriol (MC 903): Pharma-cokinetics in rats and biological activities of metabolites. A comparative study with 1,25(OH)2D3. Biochem. Pharmacol., 1991, 41, 1601-1606.